Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Chief Innovation Officer | March 16, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date March 16, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,781 |
Ending reported balance
After 2026-03-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-16 · Exercise / conversion · Acquired 6,363 · Balance 259,297 F1: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026. Row 2 · 2026-03-16 · Tax withholding · Disposed 2,870 · Balance 256,427 F2: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale. Row 3 · 2026-03-16 · Exercise / conversion · Acquired 11,575 · Balance 268,002 F1: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026. Row 4 · 2026-03-16 · Sale · Disposed 5,221 · Balance 262,781 F2: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,363 |
Reported balance
After 2026-03-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-16 · Exercise / conversion · Acquired 6,363 · Balance 6,363 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,575 |
Reported balance
After 2026-03-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-16 · Exercise / conversion · Acquired 11,575 · Balance 11,575 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.
F2: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale.
F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates.
F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2019 Filed Feb 19, 2019 18:24 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 5,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002053 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,469 F1 · shares: This reflects the number of shares that became vested as of February 15, 2019 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 15, 2019 upon the attainment of certain performance criteria. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:35 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-014316 · edgar.xml · derivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:35 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 11,900 | $0.00 Strike: $19.17 | $0.00 |
DisclosureSEC source: 0001179110-18-014316 · edgar.xml · derivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,900 Underlying: Common Stock · 11,900 shares Expires 2028-12-27 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 22:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 274 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001179110-18-012900 · edgar.xml · derivative · entry 5 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 274 shares Expires 2018-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 22:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 35,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-18-012900 · edgar.xml · derivative · entry 4 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2018-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 22:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 274 | $0.27 | $73.98 |
DisclosureSEC source: 0001179110-18-012900 · edgar.xml · nonDerivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 22:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 2,882 | $33.28 | $95,912.96 |
DisclosureSEC source: 0001179110-18-012900 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,136 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 35,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 32,118 shares of common stock. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 22:18 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 35,000 | $2.74 | $95,900.00 |
DisclosureSEC source: 0001179110-18-012900 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 35,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 32,118 shares of common stock. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015743 · edgar.xml · derivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:54 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 13,900 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015743 · edgar.xml · derivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,900 Underlying: Common Stock · 13,900 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| March 14, 2017 Filed Mar 14, 2017 23:32 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 359 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001179110-17-004610 · edgar.xml · derivative · entry 4 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 359 shares Expires 2017-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2017 Filed Mar 14, 2017 23:32 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 4,659 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001179110-17-004610 · edgar.xml · derivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,659 shares Expires 2017-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2017 Filed Mar 14, 2017 23:32 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 359 | $0.27 | $96.93 |
DisclosureSEC source: 0001179110-17-004610 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2017 Filed Mar 14, 2017 23:32 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 4,659 | $0.27 | $1,257.93 |
DisclosureSEC source: 0001179110-17-004610 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 21:45 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 50,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001179110-17-000084 · edgar.xml · derivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-12-29 F1 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option will be fully vested on December 29, 2020(4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2017(12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.